Crisaborole Patent Expiration

Crisaborole is Used for managing mild to moderate atopic dermatitis. It was first introduced by Anacor Pharmaceuticals Inc in its drug Eucrisa on Dec 14, 2016.


Crisaborole Patents

Given below is the list of patents protecting Crisaborole, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Eucrisa US8168614

(Pediatric)

Boron-containing small molecules as anti-inflammatory agents Jul 20, 2030 Anacor Pharms Inc
Eucrisa US8168614 Boron-containing small molecules as anti-inflammatory agents Jan 20, 2030 Anacor Pharms Inc
Eucrisa US8039451

(Pediatric)

Boron-containing small molecules Dec 29, 2029 Anacor Pharms Inc
Eucrisa US8039451 Boron-containing small molecules Jun 29, 2029 Anacor Pharms Inc
Eucrisa US8501712

(Pediatric)

Boron-containing small molecules as anti-inflammatory agents Aug 16, 2027 Anacor Pharms Inc
Eucrisa US9682092

(Pediatric)

Boron-containing small molecules as anti-inflammatory agents Aug 16, 2027 Anacor Pharms Inc
Eucrisa US8501712 Boron-containing small molecules as anti-inflammatory agents Feb 16, 2027 Anacor Pharms Inc
Eucrisa US9682092 Boron-containing small molecules as anti-inflammatory agents Feb 16, 2027 Anacor Pharms Inc



Crisaborole's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List